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Summary
 
A major challenge in current research into aging using model
organisms is to establish whether different treatments
resulting in slowed aging involve common or distinct
mechanisms. Such treatments include gene mutation,
dietary restriction (DR), and manipulation of reproduction,
gonadal signals and temperature. The principal method
used to determine whether these treatments act through
common mechanisms is to compare the magnitude of the
effect on aging of each treatment separately with that
when two are applied simultaneously. In this discussion
we identify ﬁve types of methodological shortcomings
that have marred such studies. These are (1) submaximal
lifespan-extension by individual treatments, e.g. as a result
of the use of hypomorphic rather than null alleles; (2) effects
of a single treatment on survival through more than one
mechanism, e.g. pleiotropic effects of lifespan mutants;
(3) the difﬁculty of interpreting the magnitude of increases
in lifespan in double treatments, and failure to measure
and model age-speciﬁc mortality rates; (4) the non-speciﬁc
effects of life extension suppressors; and (5) the possible
occurrence of artefactual mutant interactions. When
considered in the light of these problems, the conclusions
of a number of recent lifespan interaction studies appear
questionable. We suggest six rules for avoiding the
pitfalls that can beset interaction studies.
Key words: aging; epistasis; insulin/IGF signalling; dietary
restriction; 
 
Caenorhabditis elegans
 
; biodemography.
 
Introduction
 
Aging is a process of intrinsic physiological decline apparent
demographically as an increase in mortality and decline in
fecundity at later adult ages. Although the mechanisms that
determine the rate of aging are unknown, a growing number
of experimental interventions have been shown to slow demo-
graphic aging, or to increase lifespan, often used as an indication
of the rate of aging. Recently, numerous studies have attempted
to establish whether different forms of intervention into the aging
process act on the same, unidentiﬁed lifespan-determining mech-
anismµr on different ones (Dorman 
 
et al
 
., 1995; Vanﬂeteren &
De Vreese, 1995; Lakowski & Hekimi, 1996, 1998; Apfeld &
Kenyon, 1999; Hsin & Kenyon, 1999; Gems & Riddle, 2000;
Bartke 
 
et al
 
., 2001). A salient example is reduced insulin/IGF
signalling (IIS) and dietary restriction (DR). Mutations in IIS genes
increase lifespan in the nematode 
 
Caenorhabditis elegans
 
 and
the fruitﬂy 
 
Drosophila melanogaster
 
 (reviewed in Partridge &
Gems, 2002). Lifespan is also increased by DR in a number of
animal groups, including nematodes (e.g. Klass, 1977; Lakowski
& Hekimi, 1998), insects (e.g. Chapman & Partridge, 1996;
Nusbaum & Rose, 1999) and mammals (e.g. McCay 
 
et al
 
., 1935;
Masoro 
 
et al.
 
, 1982). It has been suggested that the effect
of nutritional status on lifespan in DR is mediated by insulin
(Kimura 
 
et al
 
., 1997), or IGF-I (Gems & Partridge, 2001). This
hypothesis has been addressed in 
 
C. elegans
 
 by two studies
examining the effects of interactions between DR and IIS
mutations on lifespan (Vanﬂeteren & De Vreese, 1995; Lakowski
& Hekimi, 1998). These studies employed life-extending muta-
tions in the IIS genes 
 
age-1
 
 and 
 
daf-2
 
 (Friedman & Johnson, 1988;
Kenyon 
 
et al
 
., 1993; Morris 
 
et al
 
., 1996; Kimura 
 
et al
 
., 1997).
Based partly on the ﬁnding that DR increased the lifespan of
IIS mutants, both studies concluded that these two treatments
act on different determinants of longevity and aging.
We call this kind of study of the interactions between dif-
ferent treatments affecting lifespan ‘lifespan interaction studies’.
The following discussion ﬁrst assesses the way that such studies
have been designed and the rationale that underlies their inter-
pretation, then closely examines several such studies involving
 
C. elegans
 
, 
 
Drosophila
 
 and the mouse in the light of this assess-
ment. Our analysis leads us to conclude that recent studies of
interactions between treatments that retard aging are a morass
of confusion and contradictions. We identify ﬁve types of problem
associated with interaction studies, and propose six rules for
designing and interpreting them so as to minimize the difﬁculties.
 
Lifespan interaction studies: the simple view
 
The published studies of interactions between mutations or
treatments affecting lifespan employ a logic generally similar to
classical genetic epistasis analysis. The more common under-
standing of the term epistasis is that of Mendelian geneticists;
here, when the effects on one locus mask those of another, the
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former gene is said to be epistatic to the latter, which is said
to be hypostatic (Avery & Wasserman, 1992; Huang & Sternberg,
1995). However, the term epistasis is also sometimes used to
describe any situation where the effects of two loci are non-
additive; this more inclusive deﬁnition of epistasis is current
among quantitative geneticists (for a discussion of the different
uses of the term epistasis, see Phillips, 1998). In both conceptions
of epistasis, additive effects on the trait are taken to indicate
that the interventions act through different mechanisms.
Non-additive effects (where the magnitude of the effect of one
intervention depends upon whether the other is also present)
are taken to indicate that the treatments interact in their deter-
mination of trait value. This ﬁnding in turn is taken to indicate
that the interventions act in the same pathway or process in
the determination of trait value.
The logic of interaction studies involving lifespan may be illus-
trated by three hypothetical genes affecting lifespan, 
 
a
 
, 
 
b
 
 and
 
c
 
. Suppose that mutations in either 
 
a
 
, 
 
b
 
 or 
 
c
 
 increase lifespan.
The following double mutants may be constructed: (
 
a
 
 + 
 
b
 
),
(
 
a
 
 + 
 
c
 
) and (
 
b
 
 + 
 
c
 
), and lifespans measured (Fig. 1a). The result
in Fig. 1(a) may be interpreted as follows: because (
 
a + b
 
)
lives no longer than 
 
a
 
 or 
 
b
 
 alone, 
 
a
 
 and 
 
b
 
 are involved in the
same mechanism of lifespan determination. Furthermore, this
mechanism is different from that mediating the effect of 
 
c
 
,
because the addition of 
 
c
 
 to 
 
a
 
 or 
 
b
 
 further increases lifespan.
(A less parsimonious interpretation is that 
 
a
 
 and 
 
b
 
 extend
lifespan via different mechanisms, but a pleiotropic deleterious
effect of 
 
a
 
 blocks any further extension of lifespan by 
 
b
 
, and/or
vice versa).
Examples of the (
 
a
 
 + 
 
b
 
) case in 
 
C. elegans
 
 are the interaction
between 
 
eat-2(ad465)
 
 (which causes DR due to an eating
defect) and 
 
clk-1(e2519)
 
 (Lakowski & Hekimi, 1998), and 
 
age-
1(hx546)
 
 and 
 
daf-2(e1370)
 
 (Dorman 
 
et al
 
., 1995). There is no
increase in lifespan in the double mutant compared with either
mutant alone. Examples of the (
 
a
 
 + 
 
c
 
) case are interactions
between 
 
daf-2(e1370)
 
 and 
 
clk-1(e2519)
 
 (Lakowski & Hekimi,
1996), 
 
daf-2(e1370)
 
 and 
 
eat-2(ad465)
 
 (i.e. DR) (Lakowski &
Hekimi, 1998), 
 
daf-2(e1370)
 
 or 
 
age-1(hx546)
 
 and DR due to
culture under axenic conditions (Vanﬂeteren & De Vreese, 1995),
 
daf-2
 
 (several alleles) and ablation of the germ line (Hsin &
Kenyon, 1999), and 
 
daf-2
 
 (several alleles) and maleness (Gems
& Riddle, 2000). A recent (
 
a
 
 + 
 
c
 
) case in mammals involved DR
and the Ames dwarf mutation in mice (Bartke 
 
et al
 
., 2001).
A second form of lifespan interaction study involves epistasis
analysis using suppressors of the life-extension trait, exempliﬁed
by 
 
C. elegans daf-16(–)
 
 (Kenyon 
 
et al
 
., 1993). Suppose that life
extension resulting from 
 
a
 
 is suppressed by mutation of gene
 
d
 
. One may then examine lifespan in double mutants (
 
b
 
 + 
 
d
 
)
and (
 
c
 
 + 
 
d
 
) (Fig. 1b). We see that 
 
b
 
, like 
 
a
 
, is suppressed by 
 
d
 
,
but 
 
c
 
 is not. This might suggest that 
 
c
 
 involves a distinct mech-
anism of life extension to that of 
 
a
 
 and 
 
b
 
.
Examples of (
 
a
 
 + 
 
d
 
) or (
 
b
 
 + 
 
d
 
) interactions are those of
 
daf-16(–)
 
 (
 
d
 
) with either 
 
daf-2(e1370)
 
 (Kenyon 
 
et al
 
., 1993),
germline ablation (Hsin & Kenyon, 1999) or maleness (Gems &
Riddle, 2000). Examples of (
 
c
 
 + 
 
d
 
) are 
 
daf-16(m26)
 
 with 
 
clk-1
 
or 
 
eat-2
 
 (Lakowski & Hekimi, 1996, 1998), although these ﬁndings
have been contested (Murakami & Johnson, 1996; Braeckman
 
et al
 
., 1999, 2000).
Studies such as these have given rise to the slightly shaky
current consensus that, in 
 
C. elegans
 
, DR and the clock gene
mutations extend lifespan by a common mechanism which is
distinct from that of insulin/IGF pathway mutations (reviewed
in Gems, 1999; Vanﬂeteren & Braeckman, 1999).
 
Complications and pitfalls in lifespan 
interaction studies
 
Closer examination of the assumptions involved in data inter-
pretation, and of the data themselves, raises doubts about
the validity of the interpretation of interaction experiments in
a number of individual instances. The sources of difﬁculty may
be summarized as follows: (1) The treatment may produce a
Fig. 1 (a) Interaction studies of three mutations that extend lifespan. In this 
hypothetical case, there is either complete qualitative interaction (a + b) or 
no interaction at all (a + c, b + c). In reality, complex quantitative effects may 
occur, and must be interpreted. (b) Epistasis analysis involving a suppressor 
of life extension, d. (c) An interaction study between two mutations that 
extend lifespan.
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submaximal effect on its target, e.g. mutant alleles employed
may be hypomorphic (partial loss of function) rather than null
or, when null, may fail to achieve the maximum extension of
lifespan possible by the underlying mechanism. (2) The alleles/
treatments involved affect survival through more than one
mechanism. (3) When two lifespan-extension treatments result
in lifespans greater than the single treatments, the results can
only be interpreted by analysis of age-speciﬁc mortality rates,
which is in general not performed. (4) Life extension suppressors
may reduce lifespan via deleterious effects unrelated to normal
aging. (5) There may be artefactual mutant interactions that do
not correspond to interactions between wild-type processes.
 
Interactions where loss of function is incomplete
 
If two interventions extend lifespan by the same mechanism,
but in combination act additively because they do not jointly
reach a ceiling effect (as in Fig. 1c), then it will be incorrectly
assumed that they act via different mechanisms. This may occur
either because mutant alleles are hypomorphic rather than null,
or because a given treatment results in a partial alteration in a
particular pathway or mechanism. The data in Fig.  1(c) are
therefore consistent with 
 
a
 
 and 
 
b
 
 acting via the same or via
different mechanisms. Consequently, in the absence of other
evidence, observation of interactions of type (
 
a
 
 + 
 
b
 
) are not
interpretable in terms of common or distinct life-span deter-
mining mechanisms. For example, 
 
clk-1(qm30)
 
 and 
 
clk-3(qm38)
 
extend mean lifespan (at 18 
 
°
 
C) by 33% and 37%, respectively,
whereas the lifespan of the 
 
clk-3
 
; 
 
clk-1
 
 double mutant is
increased by 192% relative to wild type (Lakowski & Hekimi,
1996). Taken alone, and by conventional inference, this result
might be taken to mean that these two mutations extend
lifespan by different mechanisms. However, since both exhibit
the same maternal effect clock (Clk) phenotype, affecting the
rate of development, feeding, defecation, etc., it has been assumed
that these mutations affect related processes (Lakowski &
Hekimi, 1996; Hekimi 
 
et al
 
., 2001). In this light, the additive
effect on lifespan indicates either than these mutations are
hypomorphic or alone produce submaximal effects on the
mechanism involved. The importance of careful characterization
of single mutant phenotypes to the correct interpretation of
mutant interaction data is discussed elsewhere (Huang &
Sternberg, 1995).
 
Effects on survival through more than one mechanism
 
Gene mutation and other treatments may have multiple effects
on the biology of an organism. Work on 
 
C. elegans
 
 has made
it clear that many different genes can increase or decrease
lifespan. It is therefore possible that multiple pleiotropic effects
of individual mutations or treatments may affect lifespan in a
complex manner. An example of this is the 
 
C. elegans
 
 insulin/
IGF receptor gene 
 
daf-2
 
. Many lifespan interaction studies have
employed the canonical allele of 
 
daf-2
 
, which is temperature
sensitive (ts), and bears the allele number 
 
e1370
 
. Null alleles of
 
daf-2
 
 are not used since they result in embryonic or early larval
lethality. Hypomorphic 
 
daf-2
 
 alleles do not vary across a single
range of mutant phenotypes, but rather fall into two distinct
allelic series. Class 1 alleles are long lived (Age). Class 2 alleles
exhibit this trait plus a complex suite of defects, including
reduced feeding, movement and fertility (Gems 
 
et al
 
., 1998).
Class 2 allele-speciﬁc pleiotropic traits are likely to affect lifespan
over and above any extension of lifespan by the Age phenotype.
Given that 
 
daf-2(e1370)
 
 is a class 2 allele, interaction studies
with 
 
clk-1
 
, 
 
eat-2
 
, dietary restriction, maleness or germline
ablation may potentially be confused by the presence of some
of the many pleiotropic defects. For example, the reduction of
feeding by 
 
daf-2(e1370)
 
 adults at higher temperatures may
confound studies of interactions between 
 
daf-2
 
 and dietary
restriction (Vanﬂeteren & De Vreese, 1995; Lakowski & Hekimi,
1998), or metabolic rate (Van Voorhies & Ward, 1999; Vanﬂeteren
& De Vreese, 1995). Moreover, studies of interactions between
 
daf-12
 
 (which mediates TGF-
 
β
 
 signalling) and different alleles
of 
 
daf-2
 
 have demonstrated that the results of interaction
studies may depend upon whether a class 1 or a class 2 
 
daf-2
 
allele is present (Larsen 
 
et al
 
., 1995; Gems 
 
et al., 1998). Thus,
more interpretable information on interactions between daf-
2(e1370) and, say, clk-1 (Lakowski & Hekimi, 1996) or eat-2
(Lakowski & Hekimi, 1998) would be obtained by using class 1
alleles of daf-2.
In higher organisms, pleiotropic mutations may well be the
rule rather than the exception (Hodgkin, 1998). Unless the
pleiotropic effects of a mutation are well characterized, there
is a danger that, as in the study of development (Huang &
Sternberg, 1995), lifespan interaction studies will lead to
erroneous conclusions. Recent studies demonstrating neuroen-
docrine regulation of aging suggest the existence of distinct
upstream and downstream determinants of aging. Thus, treat-
ments may affect distinct upstream or downstream mechanisms
(Fig. 2). Interpretation of interaction studies may be difﬁcult
if there are distinct upstream pathways regulating common
downstream mechanisms (Fig. 2b).
Interpreting quantitative interactions between 
treatments affecting lifespan
Recent studies of interactions between treatments affecting
lifespan have employed the following sort of reasoning. If two
combined treatments show no additional effect on lifespan over
either treatment alone, then they act via the same mechanism.
If the extensions of lifespan by each treatment simply add
together in the double treatment, they are independent. But
what if they are more than additive, i.e. synergistic? It is unclear
how to interpret interactions of this type, as has been noted
(Hekimi, 2001). According to the quantitative genetic concep-
tion of epistasis, such synergistic interaction may imply non-
independence (Phillips, 1998). A further problem is the exact
meaning of ‘additive’. How, precisely, may one distinguish
between additive and synergistic and when may interactions be
considered less than additive, and how should this be interpreted?
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As an illustration, consider Fig. 1(a). Let us suppose that c acts
on lifespan via a mechanism that is fully independent of a
(forget b for now). Let us also suppose that a or c alone
increases mean lifespan from 10 days to 30 days, an increase
of 200%. What effect do we expect mutation of a to have on
the lifespan of a c mutant? Mutation of a could add 20 more
days to the lifespan of the mutant, resulting in a lifespan of
50 days (a straightforward additive interaction); or it might, as
has been argued (Hekimi et al., 2001), increase its lifespan by
200%, giving a lifespan of 90 days (a multiplicative interaction).
Which is the expected interaction if the interventions act
through different pathways? Unfortunately, it is impossible to
predict the effect on mean lifespan of simultaneously applied
treatments that retard aging by independent mechanisms.
However, one may, at least, take the following measures to
deal with this problem of interpretation: taking the results of
interaction studies involving lifespan, one may calculate from
the outcomes of single treatments the predicted outcomes
assuming the null hypothesis (no interaction). Statistical tests
(e.g. analysis of variance) may then be performed to demon-
strate whether subadditive, additive or synergistic interactions
have occurred, where ‘additive’ is taken to be either arithmetic
or multiplicative.
A possible solution to the difﬁculty of deﬁning additive
interactions is to turn from survivorship or mean lifespan to
age-speciﬁc mortality – the proportion of individuals which
enter a particular age interval and which die before its conclu-
sion. Inferences about genetic effects on aging using traditional
studies of epistasis require a clear deﬁnition of the phenotypic
measure of aging, plus a scale of measure such that independent
genetic effects contribute additively to the phenotype. The problem
of choosing an appropriate scale for analysis is a general one
within quantitative biology, equally applicable, for example, to
the study of growth and body size.
There are several reasons why age-speciﬁc mortality, rather
than survivorship or mean lifespan, is a relevant measure of
aging. First, mortality rates capture age-speciﬁc changes. Infor-
mation on the timing of changes is either lost when information
is condensed into mean lifespan, or obscured when presented
in terms of survivorship. Second, age-speciﬁc patterns of mor-
tality are consistent and reproducible across different genotypes
and experimental treatments (Curtsinger et al., 1995). These
consistent patterns are often summarized quite well with
simple mathematical models (e.g. the Gompertz model). Third,
characteristic changes in the dynamics of mortality can indicate
different physiological effects. For example, a two-fold increase
in lifespan may result from either a delay in the onset of senes-
cence (a delay in the increase in mortality with age, Fig. 3a, left)
or from a slowing of the rate of physiological decline after its
onset (a slowing of the rate of increase in mortality with age,
Fig. 3b, left) (Pletcher et al., 2000). Lastly, a study of the most
likely scale for genetic effects on aging suggests that, for seg-
regating genetic variants and spontaneous mutations, genetic
effects on log mortality are most likely to be additive (Promislow
& Tatar, 1998).
Accepting age-speciﬁc mortality as the relevant measure of
aging, it immediately becomes apparent that the analysis of
interactions between treatment effects on mean lifespan can
be seriously problematical. As an example, consider two exper-
imental manipulations: one that simply shifts the mortality curve
such that the risk of death is proportionately higher or lower
throughout life (Fig. 3a), and a second that inﬂuences predom-
inantly the rate of aging (Fig. 3b). Examples of such manipula-
tions in Drosophila include dietary restriction (Pletcher et al.,
2002) and the single-gene mutant Indy, respectively (Rogina
et al., 2000). If we assume, hypothetically, that these manipu-
lations increase lifespan through entirely independent mech-
anisms, then what is the expected lifespan from an Indy mutant
raised under DR? A reasonable expectation is that the double
manipulation would both reduce the rate of aging and shift the
mortality to a lower level throughout life, and that there would
be an additive effect on age-speciﬁc mortality (Fig. 3c, left).
When considered at the level of survivorship, however, strong
synergistic epistasis is suggested (Fig. 2c, right), which taken
alone might lead to the conclusion of non-independence. Here,
average longevities are: wild-type, 13 days; mutant a, 27 days;
mutant b, 27 days; and double mutant, 71 days. It should be
pointed out that one cannot generalize to say that all interactions
Fig. 2 Interaction studies may involve different elements of hierarchies of 
upstream and downstream determinants of aging, making the interpretation 
of results problematic.
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between mutations of type ‘a’ and type ‘b’ lead to synergistic
increases in mean lifespan. However, additive effects on mean
lifespan do always occur when two treatments both shift the
age-speciﬁc mortality curve (Fig. 3d) or when they both result
in small changes in the rate of increase of mortality with age
(Fig. 3e). In this case, additive means simply additive, and not
multiplicative; i.e. returning to the above example, if a or
c alone both increase mean lifespan from 10 to 30 days via a
right shift in the mortality curve, an additive interaction in an
(a + c) double mutant would result in a mean lifespan of
50 days. We will present elsewhere a detailed account of the
predicted effects of simultaneous application of non-interacting
life extending treatments on age-speciﬁc mortality and mean
lifespan.
Another important possibility is that mutations have inde-
pendent and age-speciﬁc effects. For example, a mutation that
reduces instantaneous costs of reproduction might reduce mor-
tality rates only during reproductive ages (Partridge & Andrews,
1985; Partridge, 1999), or prevent a delayed wave of mortality
(Sgrò & Partridge, 1999). Let us suppose that such a mutation
is combined with a second that acts independently of the ﬁrst
and reduces mortality only at much later ages (say via attenu-
ation of oxidative damage). An example of such a situation is
given in Fig. 4. For these strains, average longevity is 19.2, 26.5,
43.1 and 73.1 days for the wild type, mutant line 1, mutant
line 2 and double mutant, respectively. Mutant 1 alone causes
a 7.3-day (38%) increase in lifespan, while mutant 2 alone
results in a 23.9-day (124%) increase in lifespan. Under a naive
expectation of independent effects on longevity, the double
mutant would be expected to live approximately either 50 days
(simple additive), or 59 days (multiplicative). The greater lifespan
of the double mutants (at 73 days, an increase of 265% over
wild type) might suggest epistatic interactions between the
mutations. In reality, however, examination of age-speciﬁc mor-
tality would make clear that these mutations act independently
and at different times in life.
In conclusion, interpreting relationships based on changes in
average lifespan and survivorship will produce results that are
likely to be uninterpretable and sometimes misleading. Consider
interactions between DR and reduced IIS in C. elegans. The
mean lifespan of daf-2(e1370) mutants fed on E. coli is typically
around double that of wild type (Kenyon et al., 1993). Culture
in deﬁned medium results in DR, which increases wild-type
lifespan by up to around 80%; under DR, mean daf-2(e1370)
lifespan was 191% longer than wild-type, i.e. DR and reduced
IIS showed a synergistic interaction in their effects on mean
lifespan (Vanﬂeteren & De Vreese, 1995). However, since age-
speciﬁc effects were not examined, this result cannot be taken
to mean that the two interventions act through either interact-
ing or non-interacting pathways.
Demographic analysis as a tool to identify interventions that
do not act through common pathways is potentially powerful,
but requires careful application. Use of age-speciﬁc mortality
rates rather than longevity as the phenotype for analysis will
greatly reduce the ambiguities in interpretation.
Fig. 3 Measuring mutational effects on aging. (a) Log-mortality (left) and 
survivorship (right) for a hypothetical wild-type genotype and single longevity 
enhancing mutant, which shifts the log-mortality rates down by an equal 
amount at all ages. (b) Log-mortality and survivorship for the same wild-type 
genotype and single longevity-enhancing mutant, which reduces the rate of 
increase in mortality with age. (c) Log-mortality and survivorship for the same 
wild-type genotype and a double mutant in which the effects of mutants ‘a’ 
and ‘b’ act additively and independently on mortality rates (i.e. the double 
mutant has a reduced mortality at each age and a slower rate of increase in 
mortality with age). Notice that effects on age-speciﬁc mortality that are 
additive and independent exhibit epistasis (in this case synergistic epistasis) 
on mean longevity and survivorship. (d) Not all additive interactions on age-
speciﬁc mortality exhibit epistatic effects on survivorship. Additive genetic 
effects conﬁned to ‘shifts’ in the mortality trajectory can exhibit additive 
changes in survivorship. (e) Genetic effects conﬁned to the increased rate of 
mortality with age can exhibit large or small amounts of interaction on 
survivorship depending on details of the wild-type mortality dynamics. In this 
example, mutational effects on the increased rate of mortality with age are 
exactly additive – the double mutant exhibits a change in the rate parameter 
twice that of both single mutants. A small amount of interaction is apparent 
in relation to survivorship.
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Problems of life extension suppressor studies
In studies of C. elegans, the difﬁculty of interpreting interactions
of type (a + b) (Fig. 1c) has largely been glossed over by using
interaction studies with mutations that suppress life extension
(the Age phenotype) to decide the issue. daf-2 or age-1 Age
is suppressed by mutation of daf-16 (Kenyon et al., 1993;
Dorman et al., 1995; Larsen et al., 1995). According to some
reports, daf-16 fails to suppress Age resulting from mutation
of eat-2 (i.e. DR), or clk-1 (Lakowski & Hekimi, 1996, 1998).
This appears to support the division between Age resulting
from reduced insulin/IGF signalling (IIS), which requires daf-
16(+), and clk-1(–)/DR Age, which does not. However, there
are currently two problems associated with daf-16/Age sup-
pressor studies: (a) conﬂicting results; and (b) daf-16(–) alone
shortens lifespan.
Several reports suggest that clk-1 life extension requires
daf-16(+) (Murakami & Johnson, 1996; Braeckman et al., 1999,
2000). However, Lakowski & Hekimi (1998) suggested that
suppression of the clk-1 Age phenotype by daf-16(–) observed
by Murakami & Johnson (1996) was due to the slight reduction
of lifespan that daf-16(–) causes in any genetic background
(Kenyon et al., 1993; Larsen et al., 1995; Malone et al., 1996;
Lakowski & Hekimi, 1998). They presented data showing
that the slight reduction in lifespan that daf-16 produces in
eat-2 and clk-1 mutants is similar in magnitude to that
resulting from daf-16 alone (Lakowski & Hekimi, 1998); by
this view, this is an additive (or ‘subtractive’, Hekimi, 2001)
interaction between loci conferring increases and decreases in
lifespan.
However, this issue remains contentious. Braeckman et al.
(2000) examined the effect of daf-16 on clk-1(e2519) lifespan
in axenic medium (Table 1). This dataset contradicted a key ﬁnd-
ing of the Lakowski & Hekimi (1998) study. While daf-16 alone
only decreased lifespan by 10–12%, it reduced clk-1 lifespan
by 43%, removing 85% of the clk-1 extension of mean lifespan.
Nonetheless, these data also provide some support for the
Lakowski and Hekimi scheme. Firstly, DR increased the effect
of clk-1 on lifespan, so that it produced a 105% increase over
DR-ed wild-type animals. Secondly, two mutant alleles of daf-
16 produced only slight reductions in N2 lifespan, suggesting
that the increased lifespan resulting from DR does not require
daf-16(+). Thus, this data set suggests that clk-1 but not DR
requires daf-16(+), and that these two interventions therefore
involve different mechanisms.
Fig. 4 Cartoon representation of two hypothetical 
mutations that are independent and have age-
speciﬁc effects. Strains are assumed to follow the 
Gompertz mortality model (linear on the log-scale) 
and mutations are assumed to reduce the level of 
mortality over a range of ages.
Table 1 Interaction studies between DR, daf-2, clk-1 and daf-16
  
  
Trial Strain n Mean life span ± SE
1 N2 64 30.9 ± 0.8
1 clk-1(e2519) 60 63.4 ± 1.4
1 daf-16(m27); clk-1(e2519) 59 35.9 ± 1.0
2 N2 213 26.7 ± 0.4
2 daf-16(m26) 209 23.4 ± 0.4
2 daf-16(m27) 210 23.9 ± 0.4
Animals were maintained in axenic medium with added autoclaved E. coli 
at 24 °C. N2 is the wild-type strain. Reproduced from Braeckman et al. 
(2000). FUdR was also added to the N2 populations in trial 1, and all strains 
in trial 2, to prevent egg hatching. FUdR at this concentration is not known 
to affect life span.
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Artefactual mutant interactions
Even where a clear interaction between two mutations is
observed, this does not necessarily indicate that the two wild-
type processes in which the two genes function interact with
one another. An example of a possible artefactual interaction
between mutations is the effect of clk-1(e2519) and daf-
2(e1370) on oxidative stress resistance (Oxr). daf-2 but not
clk-1 adults are Oxr (as measured by resistance to the superoxide
generator Paraquat under 98% oxygen), and overexpress
sod-3, which encodes a dauer-speciﬁc manganese superoxide
dismutase (Honda & Honda, 1999). Surprisingly, clk-1 was found
to enhance dramatically Oxr and sod-3 expression when com-
bined with daf-2. The authors of this study concluded that
clk-1 has a dual role in determining longevity: in the clock
programme itself, and by interacting with insulin/IGF signalling.
Given that clk-1 alone has no effect on Oxr or sod-3 expression,
an alternative possibility is that the role of clk-1 as an enhancer
of Oxr and sod-3 overexpression is an artefactual mutant
interaction that does not correspond to interactions between
wild-type clk-1 and daf-2 genes, or the processes in which they
are involved. Arguably, artefactual mutant interactions are more
likely to occur where the genes concerned are central metabolic
regulators (e.g. daf-2 and clk-1) than with genes with highly
speciﬁc and limited roles (say genes encoding collagens or
odorant receptors).
Six ways to avoid being misled by lifespan 
interaction studies
Some of the problems identiﬁed here are difﬁcult to rectify.
However, several steps may be taken to design interaction trials
with a greater probability of interpretable results. These are
as follows: (1) Where possible, use null alleles, as deﬁned by
genetic and molecular analysis, and environmental interventions
that have been adjusted to maximize the lifespan obtainable.
Unfortunately, for some genes (e.g. daf-2), life extension is seen
in hypomorphic but not null alleles. (2) Where available, use
alleles either without complex pleiotropic effects or, failing that,
under conditions that minimize penetrance of pleiotropies. In
the case of pleiotropic genes encoding multifunctional proteins
it may be possible to select mutant alleles where a single com-
ponent of the protein, affecting lifespan, is affected. In the case
of daf-2, class 1 alleles such as daf-2(m41) may be employed
to avoid the confounding effects of class 2 speciﬁc defects
(Gems et al., 1998; Tissenbaum & Ruvkun, 1998). (3) Use more
than one allele of any gene being examined. Even with mutant
alleles where no obvious confounding pleiotropic effects are
known to occur, a wise precaution against confounding pleio-
tropic effects is to use several alleles. Of course, they may all
have similar confounding effects on lifespan. (4) To establish
whether subadditive, additive or synergistic interactions have
occurred, calculate the expected value for an additive interaction
from the effects of individual treatments on lifespan. Test both
possible meanings of additive, i.e. arithmetical or multiplicative.
Then perform a statistical comparison of predicted values and
actual outcome, to test the hypothesis. (5) Analyse interactions
quantitatively using mortality rates (or log-mortality rates) as the
phenotypic measure of aging. (6) Perform analyses over a range
of severities of one or both of the treatments used to extend
lifespan. Given the numerous problems that may confound
interaction studies performed under any given condition, a
better chance of drawing reliable conclusions about independent
or non-independent aging mechanisms may be given by studies
of interactions between treatments over a range of severities.
An example of this approach is a recent study of interactions
between DR and reduced IIS in Drosophila. Mutation of the gene
chico, which encodes an insulin receptor substrate, increases
lifespan by up to 48% in female ﬂies under replete nutritional
conditions (Clancy et al., 2001). Extension of lifespan by DR was
found to occur in chico
1 ﬂies (Clancy et al., 2002). This ﬁnding
is consistent with similar studies performed in C. elegans
(Vanﬂeteren & De Vreese, 1995; Lakowski & Hekimi, 1998) and,
potentially, mice (Bartke, 2001). Yet when chico
1 mutant lifespan
was examined over a range of nutritional conditions, it was
found to peak at a higher level of nutrition than that of wild-
type ﬂies (Clancy et al., 2002) (Fig. 5). This meant that chico
1
lifespan was less than wild type at lower levels of nutrition.
These results indicate that chico
1 ﬂies are partially DR-ed by
their genotype. These results support the opposite conclusion
to that drawn from studies of the effect of DR on a single,
replete nutritional level: the effects of DR and reduced IIS involve
common mechanisms.
Conclusions
Studies of interactions between treatments affecting lifespan
carried out by C. elegans researchers have been dogged by con-
fusion, which has resulted, at least in part, from the problems
identiﬁed in this discussion. A particular weakness has been the
lack of quantitative analysis. Perhaps such analysis has not
been performed because there is no precedent for such analysis
Fig. 5 Interaction between dietary restriction by food dilution and reduced 
insulin/IGF signalling (chico
1) in the determination of mean lifespan.
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leading to a clear conclusion about mechanisms of aging.
Furthermore, quantitative analysis requires more and larger trials,
and more careful control of confounding variables. While all this
may make interaction studies more tedious to perform, there
is much to be gained from this approach: not only a full under-
standing of the relationship between the mechanisms underly-
ing, e.g. reduced insulin/IGF signalling, germline signalling and
DR, but also the elusive uniﬁcation of the new genetics of aging
with biodemography, and an extension of epistasis analysis to
interpret interactions that are less or more than additive.
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